Barclays PLC Has $339,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Barclays PLC lifted its position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 201.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,151 shares of the company’s stock after purchasing an additional 52,265 shares during the quarter. Barclays PLC’s holdings in Black Diamond Therapeutics were worth $339,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDTX. Walleye Capital LLC acquired a new stake in shares of Black Diamond Therapeutics in the 3rd quarter worth about $49,000. Intech Investment Management LLC purchased a new position in shares of Black Diamond Therapeutics during the third quarter valued at approximately $56,000. Vontobel Holding Ltd. bought a new stake in Black Diamond Therapeutics during the third quarter worth $68,000. MetLife Investment Management LLC lifted its stake in Black Diamond Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 22,286 shares of the company’s stock valued at $97,000 after acquiring an additional 12,557 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Black Diamond Therapeutics during the 2nd quarter worth $133,000. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Stock Performance

Shares of BDTX opened at $2.20 on Monday. The firm has a market cap of $124.48 million, a P/E ratio of -1.65 and a beta of 2.49. Black Diamond Therapeutics, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $7.66. The business has a 50-day moving average of $2.40 and a 200 day moving average of $3.95.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.09. As a group, research analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on BDTX. Piper Sandler increased their price objective on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, November 6th. Finally, Wedbush reissued an “outperform” rating and issued a $16.00 price target on shares of Black Diamond Therapeutics in a report on Tuesday, October 8th.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.